**Table S1.** Baseline clinical, laboratory, angiographic, and procedural characteristics

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variables | C-PCI  (*n* = 470) | CR  (*n* = 432) | *p* value | C-PCI  (*n* = 470) | IR  (*n* = 140) | *p* value |
| Age (years) | 71.7 ± 9.7 | 71.3 ± 9.2 | 0.495 | 71.7 ± 9.7 | 71.2 ± 9.0 | 0.521 |
| ≥65 years, *n* (%) | 364 (77.4) | 328 (75.9) | 0.589 | 364 (77.4) | 106 (75.7) | 0.669 |
| Male, *n* (%) | 278 (59.1) | 217 (50.2) | 0.007 | 278 (59.1) | 81 (57.9) | 0.785 |
| LVEF (%) | 48.3 ± 12.6 | 49.9 ± 12.7 | 0.054 | 48.3 ± 12.6 | 46.1 ± 12.5 | 0.037 |
| <40%, *n* (%) | 116 (24.7) | 93 (21.5) | 0.262 | 116 (24.7) | 38 (27.1) | 0.556 |
| BMI (kg/m2) | 23.6 ± 3.3 | 23.9 ± 3.3 | 0.133 | 23.6 ± 3.3 | 23.54 ±3.3 | 0.456 |
| SBP (mmHg) | 133.9 ± 30.1 | 134.5 ± 29.3 | 0.762 | 133.9 ± 30.1 | 135.3 ± 31.0 | 0.624 |
| DBP (mmHg) | 78.3 ± 16.6 | 78.1 ± 15.4 | 0.844 | 78.3 ± 16.6 | 78.3 ± 15.6 | 0.974 |
| Killip class III, *n* (%) | 83 (17.7) | 75 (17.4) | 0.930 | 83 (17.7) | 26 (18.6) | 0.802 |
| Hypertension, *n* (%) | 363 (77.2) | 323 (74.8) | 0.386 | 363 (77.2) | 116 (82.9) | 0.155 |
| Diabetes mellitus, *n* (%) | 247 (52.6) | 234 (54.2) | 0.628 | 247 (52.6) | 91 (65.0) | 0.009 |
| Dyslipidemia, *n* (%) | 294 (62.6) | 294 (68.1) | 0.083 | 294 (62.6) | 84 (60.0) | 0.585 |
| Previous MI, *n* (%) | 37 (7.9) | 33 (7.6) | 0.902 | 37 (7.9) | 15 (10.7) | 0.302 |
| Previous PCI, *n* (%) | 71 (15.1) | 42 (9.7) | 0.016 | 71 (15.1) | 26 (18.6) | 0.325 |
| Previous CABG, *n* (%) | 11 (2.3) | 3 (0.7) | 0.059 | 11 (2.3) | 5 (3.6) | 0.382 |
| Previous HF, *n* (%) | 22 (4.7) | 18 (4.2) | 0.748 | 22 (4.7) | 7 (5.0) | 0.824 |
| Previous CVA, *n* (%) | 72 (15.3) | 54 (12.5) | 0.249 | 72 (15.3) | 19 (13.6) | 0.686 |
| Current smokers, *n* (%) | 98 (20.9) | 80 (18.5) | 0.403 | 98 (20.9) | 23 (16.4) | 0.278 |
| Peak CK-MB (mg/dL) | 61.1 ± 96.8 | 47.6 ± 75.9 | 0.035 | 61.1 ± 96.8 | 52.5 ± 94.5 | 0.368 |
| Peak troponin-I (ng/mL) | 35.6 ± 91.5 | 24.4 ± 60.0 | 0.084 | 35.6 ± 91.5 | 34.3 ± 88.7 | 0.834 |
| NT-ProBNP (pg/mL) | 7027.3 ± 9781.9 | 5825.1 ± 8862.6 | 0.069 | 7027.3 ± 9781.9 | 7015.4 ± 8725.4 | 0.765 |
| Hs-CRP (mg/dL) | 9.4 ± 32.9 | 10.8 ± 45.8 | 0.600 | 9.4 ± 32.9 | 5.5 ± 17.4 | 0.067 |
| Serum creatinine (mg/L) | 2.41 ± 2.45 | 2.32 ± 2.64 | 0.621 | 2.41 ± 2.45 | 2.45 ± 2.58 | 0.883 |
| eGFR, mL/min/1.73m2 | 39.6 ± 16.7 | 40.8 ± 16.5 | 0.305 | 39.6 ± 16.7 | 38.3 ± 16.8 | 0.390 |
| Blood glucose (mg/dL) | 189.4 ± 100.3 | 193.6 ± 108.1 | 0.543 | 189.4 ± 100.3 | 213.6 ± 114.7 | 0.025 |
| Total cholesterol (mg/dL) | 169.7 ± 56.8 | 174.1 ± 45.7 | 0.193 | 169.7 ± 56.8 | 172.1 ± 48.1 | 0.612 |
| Triglyceride (mg/L) | 118.2 ± 71.0 | 130.9 ± 116.3 | 0.052 | 118.2 ± 71.0 | 121.8 ± 66.0 | 0.580 |
| HDL cholesterol (mg/L) | 42.5 ± 22.2 | 40.2 ± 10.5 | 0.038 | 42.5 ± 22.2 | 42.0 ± 12.0 | 0.738 |
| LDL cholesterol (mg/L) | 103.8 ± 41.9 | 109.1 ± 35.4 | 0.040 | 103.8 ± 41.9 | 101.5 ± 38.0 | 0.542 |
| Discharge medications |  |  |  |  |  |  |
| Aspirin, *n* (%) | 451 (96.0) | 418 (96.8) | 0.522 | 451 (96.0) | 136 (97.1) | 0.518 |
| Clopidogrel, *n* (%) | 435 (92.6) | 405 (93.8) | 0.655 | 435 (92.6) | 125 (89.3) | 0.214 |
| Ticagrelor, *n* (%) | 23 (4.9) | 19 (4.4) | 0.754 | 23 (4.9) | 12 (8.6) | 0.144 |
| Prasugrel, *n* (%) | 12 (2.6) | 8 (1.9) | 0.506 | 12 (2.6) | 3 (2.1) | 0.783 |
| Cilostazole, *n* (%) | 77 (16.4) | 121 (28.0) | <0.001 | 77 (16.4) | 17 (12.1) | 0.286 |
| Beta-blocker, *n* (%) | 368 (78.3) | 339 (78.5) | 0.949 | 368 (78.3) | 110 (78.6) | 0.945 |
| ACEI, *n* (%) | 202 (43.0) | 180 (41.7) | 0.690 | 202 (43.0) | 53 (37.9) | 0.329 |
| ARB, *n* (%) | 167 (35.5) | 158 (36.6) | 0.745 | 167 (35.5) | 56 (40.0) | 0.368 |
| CCB, *n* (%) | 81 (17.2) | 64 (14.8) | 0.364 | 81 (17.2) | 24 (17.1) | 0.980 |
| Lipid lowering agents, *n* (%) | 360 (76.6) | 348 (80.6) | 0.148 | 360 (76.6) | 122 (87.1) | 0.007 |
| Angiographic & procedural characteristics | | | | | | |
| IRA |  |  |  |  |  |  |
| Left main, *n* (%) | 17 (3.6) | 22 (5.1) | 0.326 | 17 (3.6) | 14 (10.0) | 0.007 |
| LAD, *n* (%) | 190 (40.4) | 151 (35.0) | 0.189 | 190 (40.4) | 51 (36.4) | 0.421 |
| LCx, *n* (%) | 105 (22.3) | 114 (26.4) | 0.157 | 105 (22.3) | 29 (20.7) | 0.683 |
| RCA, *n* (%) | 158 (33.6) | 145 (33.6) | 0.987 | 158 (33.6) | 46 (32.9) | 0.867 |
| Treated vessel |  |  |  |  |  |  |
| Left main, *n* (%) | 21 (4.5) | 38 (8.8) | 0.010 | 21 (4.5) | 18 (12.9) | 0.001 |
| LAD, *n* (%) | 217 (46.2) | 321 (74.3) | <0.001 | 217 (46.2) | 99 (70.7) | <0.001 |
| LCx, *n* (%) | 131 (27.9) | 284 (65.7) | <0.001 | 131 (27.9) | 68 (48.6) | <0.001 |
| RCA, *n* (%) | 180 (38.3) | 247 (57.2) | <0.001 | 180 (38.3) | 70 (50.0) | 0.013 |
| Extent of CAD |  |  |  |  |  |  |
| 2-vessel disease, *n* (%) | 229 (48.7) | 227 (52.5) | 0.258 | 229 (48.7) | 43 (30.7) | <0.001 |
| ≥ 3-vessel disease, *n* (%) | 241 (51.3) | 205 (47.5) | 0.258 | 241 (51.3) | 97 (69.3) | <0.001 |
| ACC/AHA lesion type |  |  |  |  |  |  |
| Type B1, *n* (%) | 62 (13.2) | 54 (12.5) | 0.766 | 62 (13.2) | 24 (17.1) | 0.238 |
| Type B2, *n* (%) | 154 (32.8) | 154 (35.6) | 0.362 | 154 (32.8) | 26 (18.6) | 0.001 |
| Type C, *n* (%) | 224 (47.7) | 196 (45.4) | 0.491 | 224 (47.7) | 76 (54.3) | 0.169 |
| Pre-PCI TIMI flow grade 0/1, *n* (%) | 185 (39.4) | 179 (41.4) | 0.526 | 185 (39.4) | 49 (35.0) | 0.352 |
| In-hospital GP IIb/IIIa, *n* (%) | 28 (6.0) | 17 (3.9) | 0.172 | 28 (6.0) | 8 (5.7) | 0.915 |
| Drug-eluting stentsa |  |  |  |  |  |  |
| ZES, *n* (%) | 168 (35.7) | 164 (38.0) | 0.534 | 168 (35.7) | 39 (27.9) | 0.085 |
| EES, *n* (%) | 248 (52.8) | 233 (53.9) | 0.725 | 248 (52.8) | 88 (62.9) | 0.035 |
| BES, *n* (%) | 54 (11.5) | 47 (10.9) | 0.833 | 54 (11.5) | 19 (13.6) | 0.505 |
| Others, *n* (%) | 6 (1.3) | 6 (1.4) | 0.883 | 6 (1.3) | 1 (0.7) | 0.583 |
| IVUS, *n* (%) | 68 (14.5) | 99 (22.9) | 0.001 | 68 (14.5) | 39 (27.9) | <0.001 |
| OCT, *n* (%) | 1 (0.2) | 1 (0.2) | 0.952 | 1 (0.2) | 1 (0.7) | 0.407 |
| FFR, *n* (%) | 3 (0.6) | 1 (0.2) | 0.626 | 3 (0.6) | 1 (0.7) | 0.922 |
| Completeness of multivessel PCI |  |  |  |  |  |  |
| CR, *n* (%) | - | 432 (100.0) | - | - | - | - |
| IR, *n* (%) |  | - | - |  | 140 (100.0) | - |
| PCI for non-IRA | - |  |  | - |  |  |
| During index PCI, *n* (%) | - | 315 (72.9) | - | - | 87 (62.1) |  |
| Staged PCI before discharge, *n* (%) | - | 117 (27.1) | - | - | 53 (37.9) |  |
| Time from admission to PCI (hours) | 18.1 ± 54.6 | 22.6 ± 57.3 | 0.008 | 18.1 ± 54.6 | 22.9 ± 55.4 | 0.007 |
| Stent diameter (mm) | 3.03 ± 0.41 | 3.02 ± 0.38 | 0.622 | 3.03 ± 0.41 | 3.11 ± 0.45 | 0.060 |
| Stent length (mm) | 28.8 ± 13.4 | 28.6 ± 14.6 | 0.864 | 28.8 ± 13.4 | 30.5 ± 14.6 | 0.220 |
| Number of stent | 1.42 ± 0.70 | 2.40 ± 1.00 | <0.001 | 1.42 ± 0.70 | 2.03 ± 0.92 | <0.001 |
| GRACE risk score | 150.9 ± 27.3 | 149.7 ± 26.8 | 0.501 | 150.9 ± 27.3 | 151.4 ± 26.7. | 0.847 |
| > 140, *n* (%) | 294 (62.6) | 255 (59.0) | 0.278 | 294 (62.6) | 88 (62.9) | 0.885 |

For continuous variables, intergroup differences were evaluated with the unpaired t-test and data are expressed as mean ± standard deviation. For categorical variables, intergroup differences were analyzed using the χ2 test or, if not applicable, Fisher’s exact test and the data are expressed as count and percentage. CR, complete revascularization; IR, incomplete revascularization; LVEF, left ventricular ejection fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; HF, heart failure; CVA, cerebrovascular events; CK-MB, creatine kinase myocardial band; NT-ProBNP, N-terminal pro-brain natriuretic peptide; Hs-CRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; IRA, infarct-related artery; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; CAD, coronary artery disease; ACC/AHA, American College of Cardiology/American Heart Association; TIMI, thrombolysis in myocardial infarction; GP, glycoprotein; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent; IVUS, intravascular ultrasound; OCT, optical coherence tomography; FFR, fractional flow reserve; CR, complete revascularization; IR, incomplete revascularization; aDrug-eluting stents were composed of ZES (Resolute Integrity stent; Medtronic, Inc., Minneapolis, MN), EES (Xience Prime stent, Abbott Vascular, Santa Clara, CA; or Promus Element stent, Boston Scientific, Natick, MA), and BES (BioMatrix Flex stent, Biosensors International, Morges, Switzerland; or Nobori stent, Terumo Corporation, Tokyo, Japan).